H. Lundbeck A/S (Lundbeck), the manufacturer of eptinezumab-jjmr (VYEPTI®), is conducting the VYEPTI Pregnancy Registry. This is an observational study in pregnant women diagnosed with migraine and treated with VYEPTI during pregnancy or up to 20 weeks prior to becoming pregnant. The purpose of this study is to collect and process data of pregnant women and their unborn and newborn baby(ies) to assess the use of VYEPTI or other preventive migraine medications in pregnancy. In addition, infant health outcomes will be collected up to the infant's first birthday.

Participation in this study will help Lundbeck to determine if there are any effects of VYEPTI on pregnant women or babies whose mothers were treated with VYEPTI during pregnancy. Results from the registry study will be shared with regulatory agencies (e.g. FDA) and may be added to product labeling to provide Healthcare Providers additional prescribing information.